New triple therapy may finally knock out tough stomach bug
NCT ID NCT05874544
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether a three-drug combination containing rifabutin can wipe out Helicobacter pylori infections that didn't respond to earlier treatments. 360 adults who had failed prior therapy were randomly assigned to one of three regimens. The goal was to see which approach had the highest eradication rate six weeks after treatment ended.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rifabutin (antibiotic) combined with vonoprazan (acid reducer) and amoxicillin (antibiotic)
What this could lead to
If successful, this could provide a more effective rescue treatment for people with hard-to-treat H. pylori infections, reducing the risk of ulcers and stomach cancer.
What could go wrong
This is a completed Phase 4 trial, but results may not apply to all populations. Rifabutin can cause side effects like low white blood cell counts and may not work if resistance develops.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HELICOBACTER PYLORI INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, 200127, China
-
Shanghai Songjiang District Central Hospital
Shanghai, Shanghai Municipality, China
-
The Second Affiliated Hospital of Zhejiang University school of Medicine
Hangzhou, Zhejiang, China